Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUCIA: EYP-1901 vs aflibercept in wet AMD
2024-518030-83-00Phase 3Authorised
- Sponsor
- EyePoint Pharmaceuticals
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of vorolanib in exudative macular degeneration (2 arms), sponsored by EyePoint Pharmaceuticals. Primary endpoint: Primary visual acuity efficacy endpoint at Week 56. Planned start May 2025; status: authorised.
02
Drugs
vorolanib
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2024-518030-83-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518030-83-00.